Edwards Lifesciences (NYSE:EW) Price Target Increased to $105.00 by Analysts at Mizuho

Edwards Lifesciences (NYSE:EW - Free Report) had its price objective hoisted by Mizuho from $95.00 to $105.00 in a research note released on Thursday morning, Benzinga reports. The firm currently has a buy rating on the medical research company's stock.

Several other research firms also recently issued reports on EW. Wells Fargo & Company upgraded Edwards Lifesciences from an equal weight rating to an overweight rating and set a $94.00 price objective on the stock in a report on Friday, February 2nd. Evercore ISI increased their price target on shares of Edwards Lifesciences from $86.00 to $92.00 and gave the stock an in-line rating in a research report on Thursday, April 4th. Royal Bank of Canada raised their price objective on shares of Edwards Lifesciences from $82.00 to $95.00 and gave the company an outperform rating in a research note on Wednesday, February 7th. Stifel Nicolaus upped their target price on shares of Edwards Lifesciences from $70.00 to $83.00 and gave the stock a hold rating in a research note on Wednesday, February 7th. Finally, Morgan Stanley raised their price target on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the company an overweight rating in a research report on Thursday, March 21st. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $91.33.

Edwards Lifesciences Trading Down 0.1 %

EW traded down $0.10 on Thursday, hitting $91.41. The company had a trading volume of 2,446,476 shares, compared to its average volume of 3,931,911. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. The firm has a market cap of $55.02 billion, a P/E ratio of 39.77, a PEG ratio of 4.57 and a beta of 1.05. The company's fifty day moving average price is $89.67 and its 200 day moving average price is $77.44. Edwards Lifesciences has a 1 year low of $60.57 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.64. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The business had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.50 billion. During the same period in the previous year, the firm earned $0.64 EPS. The business's revenue was up 13.3% on a year-over-year basis. As a group, equities analysts expect that Edwards Lifesciences will post 2.76 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,255 shares of the business's stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the sale, the chief financial officer now owns 19,248 shares in the company, valued at $1,506,925.92. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CFO Scott B. Ullem sold 7,255 shares of the stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the transaction, the chief financial officer now directly owns 19,248 shares of the company's stock, valued at approximately $1,506,925.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 10,000 shares of Edwards Lifesciences stock in a transaction on Friday, January 12th. The stock was sold at an average price of $75.67, for a total transaction of $756,700.00. Following the sale, the vice president now owns 39,503 shares in the company, valued at $2,989,192.01. The disclosure for this sale can be found here. Insiders have sold a total of 204,004 shares of company stock worth $17,922,954 over the last ninety days. Corporate insiders own 1.27% of the company's stock.

Institutional Trading of Edwards Lifesciences

Large investors have recently made changes to their positions in the company. Moneta Group Investment Advisors LLC grew its position in Edwards Lifesciences by 104,971.3% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company's stock worth $1,148,938,000 after purchasing an additional 15,384,593 shares during the last quarter. Norges Bank acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $658,390,000. Brown Advisory Inc. grew its holdings in shares of Edwards Lifesciences by 20.1% during the fourth quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company's stock worth $1,386,333,000 after buying an additional 3,048,274 shares during the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST increased its position in Edwards Lifesciences by 440.0% in the 3rd quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 3,510,000 shares of the medical research company's stock valued at $243,173,000 after acquiring an additional 2,860,000 shares during the period. Finally, CIBC Private Wealth Group LLC raised its stake in Edwards Lifesciences by 197.0% during the 4th quarter. CIBC Private Wealth Group LLC now owns 3,446,758 shares of the medical research company's stock valued at $262,815,000 after acquiring an additional 2,286,119 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.